| ABSTRACT Objective:To investigate the efficacy and safety of ivabradine combined with routine treatment of patients with chronic heart failure. Methods:90 patients were randomly divided into ivabradine group and routine treatment group. Routine anti heart failure treatment was given to the patients in the routine treatment group. The patients in the ivabradine group were treated with ivabradine 5 mg twice a day additional for 12 weeks . The changes of NYHA classification, resting heart rate, left ventricular ejection fraction (EF), plasma N-terminal pro brain natriuretic peptide (BNP), 6-minute walk test, cardiovascular death and worsening admission events of heart failure were recorded and compared before and after treatment. The safety of the two groups were evaluated. Results:The incidence of cardiovascular death or heart failure in the ivabradine group were significantly lower than that of the routine treatment group after 12 weeks of treatment (P＜0.05). The total effective rate of ivabradine group was much higher than the routine treatment group (P＜0.05). After the treatment, the heart rate, LVEF, BNP levels, 6-minute walking distance of two groups were improved better than before (P＜0.05), and the ivabradine group was superior to the routine treatment group. The incidence rate of heart failure in ivabradine group was lower than the routine treatment group (P＜0.05). There had no statistical difference between the two groups on the adverse reactions (P＞0.05）. Conclusion:Ivabradine combined with routine treatment could significantly improve the heart function of heart failure, reduce cardiovascular death and deterioration of heart failure admission, improve the prognosis, has high safety. |
